Most meta-analyses of drug interventions have narrow scopes and many focus on specific agents

Journal of Clinical Epidemiology

Volumn 66, Issue 4, 2013, Pages 371-378

  Haidich, Anna Bettina ^a   Pilalas, Dimitrios ^b   Contopoulos Ioannidis, Despina G ^c,d   Ioannidis, John P A ^c,e  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PALO ALTO MEDICAL FOUNDATION RESEARCH INSTITUTE   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

Bias; Evidence based medicine; Industry; Meta analysis; Randomized controlled trials; Research agenda

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; IMMUNOMODULATING AGENT; PLACEBO;

ARTICLE; CLINICAL EVALUATION; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; HUMAN; INTERVENTION STUDY; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RISK;

EID: 84875268866     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2012.10.014     Document Type: Review

References (50)

1. C.D. Naylor Grey zones of clinical practice: some limits to evidence-based medicine Lancet 345 1995 840 842
2. C. Young, and R. Horton Putting clinical trials into context Lancet 366 2005 107 108
3. N.A. Patsopoulos, A.A. Analatos, and J.P. Ioannidis Relative citation impact of various study designs in the health sciences JAMA 293 2005 2362 2366
4. K. Dickersin Health-care policy. To reform U.S. health care, start with systematic reviews Science 329 2010 516 517
5. R. Harbour, and J. Miller A new system for grading recommendations in evidence based guidelines BMJ 323 2001 334 336
6. D. Atkins, D. Best, P.A. Briss, M. Eccles, Y. Falck-Ytter, and S. Flottorp Grading quality of evidence and strength of recommendations BMJ 328 2004 1490
7. D. Moher, J. Tetzlaff, A.C. Tricco, M. Sampson, and D.G. Altman Epidemiology and reporting characteristics of systematic reviews PLoS Med 4 2007 e78
8. D. Moher, and A. Tsertsvadze Systematic reviews: when is an update an update? Lancet 367 2006 881 883
9. F. Song, S. Parekh, L. Hooper, Y.K. Loke, J. Ryder, and A.J. Sutton Dissemination and publication of research findings: an updated review of related biases Health Technol Assess 14 2010 iii, ix-xi, 1-193
10. D. Moher, A. Tsertsvadze, A.C. Tricco, M. Eccles, J. Grimshaw, and M. Sampson A systematic review identified few methods and strategies describing when and how to update systematic reviews J Clin Epidemiol 60 2007 1095 1104
11. A.W. Jorgensen, J. Hilden, and P.C. Gotzsche Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review BMJ 333 2006 782
12. V. Yank, D. Rennie, and L.A. Bero Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study BMJ 335 2007 1202 1205
13. A.C. Tricco, J. Tetzlaff, B. Pham, J. Brehaut, and D. Moher Non-Cochrane vs. Cochrane reviews were twice as likely to have positive conclusion statements: cross-sectional study J Clin Epidemiol 62 2009 380 386.e1
14. J.P. Ioannidis, N.A. Patsopoulos, and H.R. Rothstein Reasons or excuses for avoiding meta-analysis in forest plots BMJ 336 2008 1413 1415
15. J.P. Ioannidis, and F.B. Karassa The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence BMJ 341 2010 c4875
16. J.P. Ioannidis Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses CMAJ 181 2009 488 493
17. D.G. Contopoulos-Ioannidis, and J.P. Ioannidis Claims for improved survival from systemic corticosteroids in diverse conditions: an umbrella review Eur J Clin Invest 42 2012 233 244
18. T. Lumley Network meta-analysis for indirect treatment comparisons Stat Med 21 2002 2313 2324
19. D.M. Caldwell, A.E. Ades, and J.P.T. Higgins Simultaneous comparison of multiple treatments: combining direct and indirect evidence BMJ 331 2005 897 900
20. S.A. Kilburn, P. Featherstone, B. Higgins, and R. Brindle Interventions for cellulitis and erysipelas Cochrane Database Syst Rev 6 2010 CD004299
21. A. Cipriani, T. La Ferla, T.A. Furukawa, A. Signoretti, A. Nakagawa, and R. Churchill Sertraline versus other antidepressive agents for depression Cochrane Database Syst Rev 4 2010 CD006117
22. R.D. Rattehalli, M.B. Jayaram, and M. Smith Risperidone versus placebo for schizophrenia Cochrane Database Syst Rev 1 2010 CD006918
23. Who Collaborating Centre For Drug Statistics methodology. ATC classification index with DDDs. Oslo, Norway; 2012.
24. Drugs@FDA Database. Available at (www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm). Accessed December 2012.
25. Orange Book: Approved drug products with therapeutic equivalence evaluations. Available at (www.accessdata.fda.gov/scripts/cder/ob/default.cfm). Accessed December 2012.
26. ClinicalTrials.gov. Available at clinicaltrials.gov. Accessed December 2012.
27. Basow DS, ed. UpToDate: Waltham, MA; 2012.
28. M.E. Falagas, E.K. Vouloumanou, A.G. Togias, M. Karadima, A.M. Kapaskelis, and P.I. Rafailidis Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials J Antimicrob Chemother 65 2010 1862 1877
29. I.A. Bliziotis, E. Plessa, G. Peppas, and M.E. Falagas Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis Ann Pharmacother 44 2010 97 106
30. M. Bounthavong, and D.I. Hsu Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis Curr Med Res Opin 26 2010 407 421
31. L. Beibei, C. Yun, C. Mengli, B. Nan, Y. Xuhong, and W. Rui Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials Int J Antimicrob Agents 35 2010 3 12
32. A.B. Cavalcanti, A.R. Goncalves, C.S. Almeida, D.D. Bugano, and E. Silva Teicoplanin versus vancomycin for proven or suspected infection Cochrane Database Syst Rev 6 2010 CD007022
33. A. Liberati Need to realign patient-oriented and commercial and academic research Lancet 378 2011 1777 1778
34. J. Peppercorn, E. Blood, E. Winer, and A. Partridge Association between pharmaceutical involvement and outcomes in breast cancer clinical trials Cancer 109 2007 1239 1246
35. G. Salanti, A.E. Ades, and J.P. Ioannidis Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial J Clin Epidemiol 64 2011 163 171
36. E.J. Mills, J.P.A. Ioannidis, K. Thorlund, H.J. Schünemann, M.A. Puhan, and G.H. Guyatt How to use an article reporting a multiple treatments meta-analysis JAMA 308 2012 1246 1253
37. R.B. D'Agostino Sr. Changing end points in breast-cancer drug approval - the Avastin story N Engl J Med 365 2011 e2
38. J. Lexchin, L.A. Bero, B. Djulbegovic, and O. Clark Pharmaceutical industry sponsorship and research outcome and quality: systematic review BMJ 326 2003 1167 1170
39. L. Bero, F. Oostvogel, P. Bacchetti, and K. Lee Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others PLoS Med 4 2007 e184
40. B. Djulbegovic, M. Lacevic, A. Cantor, K.K. Fields, C.L. Bennett, and J.R. Adams The uncertainty principle and industry-sponsored research Lancet 356 2000 635 638
41. D.N. Lathyris, N.A. Patsopoulos, G. Salanti, and J.P. Ioannidis Industry sponsorship and selection of comparators in randomized clinical trials Eur J Clin Invest 40 2010 172 182
42. G. Salanti, F.K. Kavvoura, and J.P. Ioannidis Exploring the geometry of treatment networks Ann Intern Med 148 2008 544 553
43. E.C. Rizos, G. Salanti, D.P. Kontoyiannis, and J.P. Ioannidis Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents J Clin Epidemiol 64 2011 830 842
44. A.W. Jorgensen, K.L. Maric, B. Tendal, A. Faurschou, and P.C. Gotzsche Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions BMC Med Res Methodol 8 2008 60
45. Green S, Higgins JPT, eds. Chapter 2: Preparing a Cochrane review. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, 2008.
46. J. Davey, R.M. Turner, M.J. Clarke, and J.P. Higgins Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews: a cross-sectional, descriptive analysis BMC Med Res Methodol 11 2011 160
47. R. Smith Journals fail to adhere to guidelines on conflicts of interest BMJ 323 2001 651
48. C.A. Silagy, P. Middleton, and S. Hopewell Publishing protocols of systematic reviews: comparing what was done to what was planned JAMA 287 2002 2831 2834
49. A. Booth, M. Clarke, D. Ghersi, D. Moher, M. Petticrew, and L. Stewart An international registry of systematic-review protocols Lancet 377 2011 108 109
50. T. Li, M.A. Puhan, S.S. Vedula, S. Singh, K. Dickersin Ad Hoc Network Meta-analysis Methods Meeting Working Group Network meta-analysis-highly attractive but more methodological research is needed BMC Med 9 2011 79